Novo’s Ozempic price cut expected to slow market share erosion
Novo Nordisk’s decision to significantly reduce the price of blockbuster drug semaglutide is expected to slow the shift of patients…
Metabolic Disorders
-
-
WHO adds GLP-1RAs to essential medicines list
The World Health Organisation (WHO) has updated its model list of essential medicines (EML) to include four key obesity and…
-
EMA warns of rise in illegal weight loss drugs marketed online
The European Medicines Agency (EMA) has warned of a sharp rise in illegal medicines being sold under the guise of…
-
Chinese drugmakers prep for looming semaglutide generics horizon
Chinese pharmaceutical companies are eyeing a lucrative commercial market set to materialise upon the patent expiry for Novo Nordisk’s blockbuster…
-
Novo Nordisk enlists srRNA developer Replicate in $550m deal
Novo Nordisk has turned to Replicate Bioscience’s RNA drug platform in a lucrative research collaboration, marking the latest effort by…
-
Eli Lilly eyes orforglipron approval after Phase III diabetes trial success
Although data for Eli Lilly’s orforglipron may have disappointed investors earlier this month, a new release of Phase III data…
-
Madrigal wins European MASH approval as Novo rivalry looms
Madrigal Pharmaceuticals’ Rezdiffra (resmetirom) has been approved in Europe for the treatment of metabolic dysfunction-associated steatohepatitis (MASH) with moderate to…
-
UK pharmacist says Eli Lilly’s Mounjaro price hike a “shock”
Eli Lilly will increase the UK list price of its blockbuster drug Mounjaro (tirzepatide) amid pressure from US President Donald…
-
Eli Lilly seeks more GPCR weight loss drugs in $1.3bn research deal
Eli Lilly will pay up to $1.3bn for Superluminal Medicines to discover and progress small-molecule therapeutics for G protein-coupled receptors…
-
WeightWatchers shuns compounded semaglutide amid FDA rules
WeightWatchers has confirmed it no longer offers compounded semaglutide, instead providing patients with Novo Nordisk’s branded drug Wegovy. In its…
